Biohaven Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$48.6M
Doctors Paid
43,755
Transactions
193,120
2021 Total
$44.3M
Payment Breakdown by Category
Research$34.9M (71.7%)
Food & Beverage$4.0M (8.2%)
Consulting$1.6M (3.2%)
Travel$411,684 (0.8%)
Royalty/License$8,150 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34.9M | 4,706 | 71.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.5M | 4,811 | 15.5% |
| Food and Beverage | $4.0M | 180,079 | 8.2% |
| Consulting Fee | $1.6M | 1,159 | 3.2% |
| Travel and Lodging | $411,684 | 2,026 | 0.8% |
| Grant | $250,000 | 1 | 0.5% |
| Royalty or License | $8,150 | 9 | 0.0% |
| Education | $3,627 | 329 | 0.0% |
Payments by Type
Research
$34.9M
4,706 transactions
General
$13.7M
188,414 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | $9.5M | 0 | 1,250 |
| A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | $6.7M | 1 | 670 |
| Healey Platform Trial | $3.2M | 0 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) | $3.0M | 0 | 920 |
| A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | $2.6M | 6 | 539 |
| A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | $1.6M | 0 | 64 |
| A Phase III Long-Term Randomized Doubleblind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia | $1.3M | 0 | 82 |
| A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder | $1.2M | 0 | 209 |
| Phase 1: Open-Label 8-Week Safety Study of Oral Zavegepant (BHV-3500) in Normal Healthy Subjects | $696,702 | 0 | 38 |
| Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age | $592,689 | 0 | 160 |
| A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimers Disease | $504,775 | 0 | 66 |
| BHV3500-301: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | $487,776 | 0 | 70 |
| Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | $423,881 | 0 | 129 |
| A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder | $402,803 | 0 | 78 |
| Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder | $401,919 | 0 | 2 |
| A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | $351,183 | 0 | 72 |
| A Phase IIb/III Randomized Double-blind Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia | $237,599 | 0 | 33 |
| Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age | $229,763 | 0 | 75 |
| Phase 2/3 Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients with COVID-19 Requiring Supplemental Oxygen | $200,831 | 0 | 16 |
| A Phase III, Long-Term, Randomized, Doubleblind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia | $160,544 | 0 | 21 |
| A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention | $155,550 | 0 | 56 |
| A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder | $147,039 | 0 | 45 |
| A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebellar Ataxia | $128,024 | 0 | 7 |
| A randomized, double-blind, placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder | $121,073 | 0 | 20 |
| Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | $100,709 | 0 | 2 |
| A Phase 2 Double Blind Placebo Controlled Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia | $84,817 | 0 | 16 |
| Multicenter open-label single dose study to evaluate the safety tolerability and single-dose pharmacokinetics of rimegepant in children ( 6 to < 12 years of age) with a history of migraine | $82,882 | 0 | 23 |
| Multicenter open-label single dose study to evaluate the safety tolerability and single-dose pharmacokinetics of rimegepant in children (? 6 to < 12 years of age) with a history of migraine | $67,847 | 0 | 12 |
| HEALEY ALS Platform Trial - Regimen B Verdiperstat | $50,973 | 0 | 2 |
| Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients | $46,200 | 1 | 14 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Steven Schnittman, M.d, M.D | Infectious Disease | West Haven, CT | $142,500 | $0 |
| Jaclyn Duvall, Md, MD | Neurology | Tulsa, OK | $140,929 | $0 |
| Dr. Katherine Standley, Do, DO | Neurology | Tampa, FL | $124,142 | $0 |
| Eric Eross, Do, DO | Specialist | Phoenix, AZ | $121,627 | $0 |
| Dr. Shivang Joshi, Md, MD | Neurology | Westborough, MA | $117,781 | $0 |
| Dr. Kasra Maasumi, M.d, M.D | Neurology | Rancho Santa Margarita, CA | $115,212 | $0 |
| Nicolas Saikali, Md, MD | Neurology | Amherst, NY | $110,471 | $0 |
| Stephen Landy, Md, MD | Neurology | Tupelo, MS | $109,256 | $0 |
| Thomas Shiovitz, Md, MD | Psychiatry | Sherman Oaks, CA | $91,580 | $0 |
| Jeffrey Groves, Md, MD | Neurology | Draper, UT | $77,891 | $0 |
| Dr. Jack Schim, M.d, M.D | Neurology | Carlsbad, CA | $77,600 | $0 |
| Dr. Hayden Long, Md, MD | Neurology | Mobile, AL | $74,032 | $0 |
| Julio Cantero, Md, MD | Sleep Medicine | Sarasota, FL | $73,603 | $0 |
| Ravi Shah, Md, MD | Neurology | Parker, CO | $72,725 | $0 |
| Dr. Gerald Sacks, M.d, M.D | Pain Medicine | Santa Monica, CA | $69,667 | $0 |
| Catherine Ham, Md, MD | Neurology | Richmond, VA | $67,311 | $0 |
| Dr. V Kassicieh, D.o, D.O | Neurology | Sarasota, FL | $66,595 | $0 |
| Dr. Raghav Govindarajan, Md, MD | Neurology | O Fallon, IL | $66,505 | $0 |
| Dr. Eric Baron, D.o,, D.O, | Neurology | Cleveland, OH | $61,586 | $0 |
| John Chawluk, M.d, M.D | Neurology | Pottsville, PA | $61,034 | $0 |
| Dr. Chaouki Khoury, Md, Ms, MD, MS | Neurology with Special Qualifications in Child Neurology | Atlanta, GA | $60,547 | $0 |
| Dr. Andrew Blumenfeld, M.d, M.D | Neurology | Los Angeles, CA | $59,500 | $0 |
| Dr. Kevin Kahn, Md, MD | Neurology | Durham, NC | $58,570 | $0 |
| Dr. Herbert Krob, Md, MD | Neuromuscular Medicine | Portland, OR | $57,737 | $0 |
| Dr. Xu He, D.o, D.O | Internal Medicine | Redlands, CA | $57,270 | $0 |
Ad
Top Products
- NURTEC ODT $18.0M
Payment Categories
- Food & Beverage $4.0M
- Consulting $1.6M
- Travel & Lodging $411,684
- Research $34.9M
- Royalties $8,150
About Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. has made $48.6M in payments to 43,755 healthcare providers, recorded across 193,120 transactions in the CMS Open Payments database. In 2021, the company paid $44.3M. The top product by payment volume is NURTEC ODT ($18.0M).
Payments were distributed across 241 medical specialties. The top specialty by payment amount is Neurology ($6.0M to 3,125 doctors).
Payment categories include: Food & Beverage ($4.0M), Consulting ($1.6M), Research ($34.9M), Travel & Lodging ($411,684), Royalties ($8,150).